Daily Stock Analysis, BPTH, Bio Path Holdings Inc, priceseries

Bio Path Holdings Inc. Daily Stock Analysis
Stock Information
Open
11.12
Close
11.46
High
11.51
Low
11.12
Previous Close
11.11
Daily Price Gain
0.35
YTD High
73.52
YTD High Date
Mar 7, 2019
YTD Low
1.61
YTD Low Date
Jan 22, 2019
YTD Price Change
7.66
YTD Gain
201.58%
52 Week High
73.52
52 Week High Date
Mar 7, 2019
52 Week Low
1.61
52 Week Low Date
Jan 22, 2019
52 Week Price Change
-15.54
52 Week Gain
-57.56%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 12. 2017
64.00
Sep 19. 2017
68.50
5 Trading Days
7.03%
Link
LONG
Oct 6. 2017
78.00
Oct 17. 2017
90.03
7 Trading Days
15.43%
Link
LONG
Nov 16. 2018
9.00
Nov 29. 2018
9.84
8 Trading Days
9.28%
Link
LONG
Feb 28. 2019
2.60
Mar 19. 2019
25.54
13 Trading Days
882.24%
Link
Company Information
Stock Symbol
BPTH
Exchange
NasdaqCM
Company URL
http://www.biopathholdings.com
Company Phone
(832) 742-1357
CEO
Peter H. Nielsen
Headquarters
Texas
Business Address
4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE, TX 77401
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0001133818
About

Bio-Path Holdings, Inc. operates as a biotechnology company which focuses on the development of targeted therapies for acute myeloid leukemia, chronic myeloid leukemia, and other types of cancer. Its drug candidates include prexigebersen and Liposomal Bcl2. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein, and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.

Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.